Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Camille Abboud, Sr., Jan Maciej Zaucha, Scott R. Solomon, Terrence Bradley, Elie Mouhayar, Noemi Angelosanto, Hendrik Nogai, Renata Dudziak, Tomasz Rzymski, Peter Littlewood, Krzysztof Brzózka, Axel Glasmacher, Gautam Borthakur, Howard A. Burris, Sr., Ewa Lech Marańda

Blood (2022) 140 (Supplement 1): 6228–6229.

https://doi.org/10.1182/blood-2022-163150

Published: 2022

Journal Articles

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Blood (2021) 138 (Supplement 1): 2371.

https://doi.org/10.1182/blood-2021-152273

Published: 2021

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Camille Abboud, Sr., Gautam Borthakur, Scott R. Solomon, Howard A. Burris, Sr., Terrence Bradley, JAN Maciej Zaucha, Sr., Ewa Lech-Marańda, Krzysztof Brzozka, Tomasz Rzymski, Peter Littlewood, Elie Mouhayar, Setareh Shamsili, Noemi Angelosanto

Blood (2021) 138 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2021-151030

Published: 2021

Journal Articles

Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease

Iskra Pusic, Tanner Johanns, Stefanie Sarantopoulos, Haley Record, Kaitlynn Zeisset, Peter Westervelt, Amanda F. Cashen, Geoffrey L. Uy, Camille Abboud, Sr., John F. DiPersio

Blood (2021) 138 (Supplement 1): 3904.

https://doi.org/10.1182/blood-2021-146778

Published: 2021

Journal Articles

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Sr., Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 100.

https://doi.org/10.1182/blood-2021-144591

Published: 2021

Journal Articles

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134624

Published: 2020

Journal Articles

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-134948

Published: 2020

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Allogeneic HSCT for ATL: a good start

Camille Abboud

Blood (2012) 120 (8): 1541–1542.

https://doi.org/10.1182/blood-2012-07-439224

Published: 2012

Journal Articles

A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.

Ravi Vij, MD, Alissa Nelson, Geoffrey L. Uy, MD, Camille Abboud, Peter Westervelt, MD, PhD, Amanda F Cashen, MD, Stockerl-Goldstein Keith, MD, Kathryn M Trinkhaus, Ph.D., John F. DiPersio, MD, PhD, Todd A Fehniger, MD, PhD

Blood (2009) 114 (22): 842.

https://doi.org/10.1182/blood.V114.22.842.842

Published: 2009

Journal Articles

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Richard Walgren, MD, PhD, Crystal Dao, MA, Frederieke Kreisel, MD, Peter Westervelt, MD, PhD, Camille Abboud, MD, Timothy Graubert, MD, Amanda Cashen, MD, Geoffrey Uy, MD, Feng Gao, MD, John DiPersio, MD, PhD, Ravi Vij, MD

Blood (2007) 110 (11): 1451.

https://doi.org/10.1182/blood.V110.11.1451.1451

Published: 2007

Journal Articles

Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant.

James C. Mosley, III, MD, Shachar Peles, M.D., Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Camille Abboud, M.D., Amanda Cashen, M.D., Geoffrey Uy, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M. D., Ph.D., Ravi Vij, M.D.

Blood (2007) 110 (11): 5109.

https://doi.org/10.1182/blood.V110.11.5109.5109

Published: 2007

Journal Articles

The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.

Tanya M. Wildes, MD, Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Geoffrey Uy, M.D., Amanda Cashen, M.D., Camille Abboud, M.D., Peter Westervelt, M.D., Ph.D., John F. Dipersio, M.D., Ph.D., Ravi Vij, M.D.

Blood (2007) 110 (11): 1182.

https://doi.org/10.1182/blood.V110.11.1182.1182

Published: 2007

NARROW

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation

Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

High Doses of Targeted Radiation with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Allogeneic HSCT for ATL: a good start

A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant.

The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only